Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Maraviroc (Celsentri) With Raltegravir and Darunavir/Ritonavir for the Treatment of Triple Class Failure in Adult HIV-1 Infected Patients (TERCETO)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2009 by The Huesped Foundation.
Recruitment status was  Recruiting
Information provided by:
The Huesped Foundation Identifier:
First received: November 13, 2009
Last updated: February 9, 2010
Last verified: November 2009
No Study Results Posted on for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: No date given